67. Polycystic kidney disease Clinical trials / Disease details
Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05373264 (ClinicalTrials.gov) | February 2023 | 28/4/2022 | HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life | HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life | ADPKD | Drug: Hydrochlorothiazide 25 mg;Drug: Placebo | University Medical Center Groningen | NULL | Not yet recruiting | 18 Years | 80 Years | All | 300 | Phase 3 | Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States |